(Reuters) -Axsome Therapeutics said on Tuesday its experimental drug to treat attention deficit hyperactivity disorder (ADHD) met its main goal in a late-stage study.
The drug, solriamfetol, helped ease symptoms which include difficulty paying attention, restlessness, and impulsivity in adults as measured using a common scale, the company said.
The drug was found to be safe and well tolerated in the study with no serious side-effects, Axsome said.
The company plans to begin a trial in pediatric patients this year.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shailesh Kuber)
